Last reviewed · How we verify
NCT03857477: BARCODE1
The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
trial testing Genetic SNP profiling in Prostate Cancer in 4,700 participants. Participants enrolled and being followed up; not accepting new ones.
1 April 2024
Quick facts
| Lead sponsor | Institute of Cancer Research, United Kingdom |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 4,700 |
| Start date | 14 March 2019 |
| Primary completion | 1 April 2024 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Genetic SNP profiling
- Prostate cancer screening
- MRI Scan
- Prostate biopsy
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Institute of Cancer Research, United Kingdom
Who can join
Adults 55 to 69, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. A pilot of 300 men were recruited aiming to inform the feasibility and accessibility of the study approach. The full study is an extension of the pilot study aiming to recruit a total of 5000 men.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
McHugh JK, Bancroft EK, Saunders E, Brook MN, et al · · 2025 · cited 53× · PMID 40214032 · DOI 10.1056/nejmoa2407934 -
The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.
Benafif S, Ni Raghallaigh H, McGrowder E, Saunders EJ, et al · · 2022 · cited 29× · PMID 34214236 · DOI 10.1111/bju.15535 -
Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.
Balázs K, Antal L, Sáfrány G, Lumniczky K. · · 2021 · cited 23× · PMID 33924671 · DOI 10.3390/jpm11040296 -
Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk.
Bancroft EK, Raghallaigh HN, Page EC, Eeles RA. · · 2021 · cited 12× · PMID 34790437 · DOI 10.1007/s40142-021-00202-5 -
Overview of Performance Indicators of Prostate Cancer Screening Trials.
van Harten MJ, Willemse PM, van den Bergh RCN, Roobol MJ. · · 2025 · cited 1× · PMID 40979268 · DOI 10.1016/j.euros.2025.08.004 -
Joint Biochemical and Genetic Prostate Cancer Risk Stratification.
Zeltser N, Haas R, Ibilibor C, Gelfond J, et al · · 2026 · PMID 41270226 · DOI 10.1097/ju.0000000000004859 -
Proceedings of the International Cancer Imaging Society Meeting and 20th Annual Teaching Course : ONLINE, 19 - 22 September 2021.
· 2021 · PMID 34535182 · DOI 10.1186/s40644-021-00422-6
Verify or expand the search:
- PubMed search for NCT03857477
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Genetic SNP profiling
Trials testing the same drug.
- NCT03158922 — The BARCODE 1 Pilot Study · active not recruiting
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Institute of Cancer Research, United Kingdom trials
Trials by the same sponsor.
- NCT06396754 — Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC · not yet recruiting
- NCT07391215 — 5G-PEARL: Paxalisib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
- NCT07098819 — The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography · not yet recruiting
- NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
- NCT06630260 — 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03857477 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Cancer Research, United Kingdom
- Last refreshed: 29 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03857477.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing